VYNE — VYNE Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1566044 ·
Last close
$0.68
Market Cap
$22.66M
52W High
$0.69
52W Low
$0.57
ADV30
201,639
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 86,000 | — | -3,816,000 | -3,585,000 | 25,873,000 | 24,631,000 | 1,236,000 |
| Dec 2025 | 130,000 | — | -5,219,000 | -4,837,000 | 30,160,000 | 24,027,000 | 2,395,000 |
| Sep 2025 | 169,000 | — | -7,792,000 | -7,280,000 | 36,132,000 | 19,346,000 | 4,044,000 |
| Jun 2025 | 69,000 | — | -7,542,000 | -5,755,000 | 44,718,000 | 22,047,000 | 5,836,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-33,124,000
Investing CF
$37,368,000
Financing CF
$-143,000
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.78
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-757,653,000
Inventory
—
Receivables
—
ST Investments
$4,981,000
EBIT TTM
$-29,750,000
Pretax Income TTM
$-26,732,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$454,000
EBITDA
$-24,345,000
Free Cash Flow
$-20,111,000
Enterprise Value
$-2,534,891
Total Cash
$24,928,000
Total Debt
$0
Shares Out
33,352,858
Trailing EPS
$-0.51
Book Value
$0.83
ROE
-63.2%
ROA
-37.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 570,000 | -29,749,000 | -26,483,000 | 30,160,000 | 2,395,000 | — | -33,124,000 |
| Dec 2024 | 501,000 | -43,637,000 | -39,834,000 | 66,905,000 | 14,819,000 | — | -33,972,000 |
| Dec 2023 | 424,000 | -29,258,000 | -28,452,000 | 97,685,000 | 8,950,000 | — | -25,341,000 |
| Dec 2022 | 477,000 | -34,295,000 | -23,210,000 | 40,758,000 | 9,556,000 | — | -29,200,000 |
TTM Snapshot
Revenues TTM
$3,269,000
NetIncome TTM
$47,875,000
OpCashFlow TTM
$0
Assets (Latest)
$93,742,000
Forward EPS
$-1.65
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KTTA | Pasithea Therapeutics Corp. | $22.73M | $0.68 | — |
| HOWL | Werewolf Therapeutics, Inc. | $22.51M | $0.46 | — |
| SNSE | Sensei Biotherapeutics, Inc. | $22.10M | $16.47 | — |
| AYTU | AYTU BIOPHARMA, INC | $23.40M | $2.18 | — |
| TRAW | Traws Pharma, Inc. | $23.94M | $1.58 | — |
News headlines (Yahoo Finance, 1h cache)
BC-Most Active Stocks
2025-12-17 15:30 · Yahoo
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
2025-12-17 13:00 · Yahoo
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
2025-11-06 14:15 · Yahoo
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update
2025-11-06 13:00 · Yahoo
VYNE Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
2025-08-18 18:37 · Yahoo
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
2025-08-14 13:15 · Yahoo
VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
2025-08-14 12:00 · Yahoo
Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates
2025-08-12 21:40 · Yahoo
Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates
2025-08-11 22:55 · Yahoo
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates
2025-08-06 22:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.